Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04938869 Completed - Clinical trials for Type 2 Diabetes Mellitus

Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer

Start date: October 5, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies the effect of a continuous glucose monitor application in improving outcomes in patients with poorly controlled type 2 diabetes and active cancer. Patient satisfaction with type 2 diabetes management influences medication-taking behavior as well as health outcomes. Adding continuous glucose monitor application to diabetes treatment plan after hospital discharge plan may improve patient satisfaction and reduce diabetes distress.

NCT ID: NCT04937842 Recruiting - Solid Tumors Clinical Trials

Microtransplantation for Advanced and Relapsed Solid Tumors

Start date: June 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, we will apply micro transplantation to the field of solid tumors to study the efficacy and safety of radiotherapy and chemotherapy combined with micro transplantation in the treatment of advanced / relapsed solid tumors.

NCT ID: NCT04937647 Recruiting - Clinical trials for Gastrointestinal Neoplasms

Evaluation of Neoplasia With Artificial Intelligence in Gastrointestinal Endoscopy

NEW-AGE
Start date: June 16, 2021
Phase:
Study type: Observational

This study aims to validate and evaluate AI algorithms for detection and characterization of early GI neoplasia.

NCT ID: NCT04937153 Active, not recruiting - Solid Tumor Clinical Trials

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Start date: June 15, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with pembrolizumab in Japanese study participants with malignant solid tumors.

NCT ID: NCT04936178 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of NB003 in Patients With Advanced Malignancies

Start date: August 6, 2021
Phase: Phase 1
Study type: Interventional

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

NCT ID: NCT04934514 Recruiting - Clinical trials for Advanced Solid Tumor

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Start date: July 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.

NCT ID: NCT04933825 Active, not recruiting - Clinical trials for Relapsed or Refractory B-cell Malignancy(NHL/ALL)

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.

NCT ID: NCT04933604 Completed - Surgery Clinical Trials

LPN in Patients With High-complex Renal Tumors

Start date: September 1, 2019
Phase:
Study type: Observational

The study aims to investigate the rationale for LPN in patients with high-complexity renal tumors in terms of oncologic and functional outcomes.

NCT ID: NCT04932967 Completed - Covid19 Clinical Trials

Use of nMoABs for the Treatment of COVID-19 in Patients With HM.

Start date: September 30, 2021
Phase:
Study type: Observational

This is a multicenter retrospective, non-interventional observational study to evaluate the efficacy of nMoAbs in HM patients.

NCT ID: NCT04932863 Recruiting - Neoplasms Clinical Trials

BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

UNICO
Start date: March 15, 2021
Phase:
Study type: Observational

In this Italian observational study the antibody titer reactogenicity to Pfizer Severe Acute Respiratory Syndrome (SARS) - Coronavirus (CoV-2) RNA vaccine in cancer patients under active antitumor treatment will be evaluated at 21 and 42 days and after 6 months. Furthermore patients safety will be monitored. Factors affecting immunogenicity (or lack of), including cancer treatment, will be the primary aim of the study.